by John R. Fischer
, Senior Reporter | December 31, 2018
Proton therapy manufacturer Ion Beam Applications S.A. is set to install a new proton therapy solution for a contract estimated to be worth between $28,616,400 (€25 million) and $34,339,680 (€30 million).
Under orders from the Free University of Brussels, the University of Liège, the University of Mons and the University of Namur, the Belgian-based provider will begin the installation process of its Proteus ONE compact proton therapy solution in Charleroi, located in the Wallonia Region of Belgium. The Walloon Government confirmed its obtainment of financing for the project earlier this month, with a full down payment expected to be delivered to IBA soon.
IBA was selected as the preferred vendor in February 2017 following a comprehensive European public tender process. The agreement includes the supply of equipment and a service contract with IBA, as well as research program collaborations with the four universities. In addition, the Catholic University of Louvain will participate in complementary research programs with the four too.
The installation of the compact single-room solution will be the second carried out by IBA in Belgium and its 25th overall. It is the seventh Proteus One contract to be signed this year, with three still awaiting financing and one a term sheet for which IBA has already obtained a down payment.
The news also follows the recent authorization of the solution in the Brazilian market
. "This is an exciting milestone for our potential customers in Brazil, where the cost of healthcare is a major focus," Olivier Legrain, chief executive officer of IBA, said in a statement. "Much smaller and more affordable than conventional multi-room proton therapy systems, but with the same clinical applications, Proteus ONE makes proton therapy more accessible both to clinical institutions worldwide and to their cancer patients."
IBA is a provider of universal, full-scale and compact, single-room PT centers as well as particle accelerators and radiation dosimetry solutions, for which it recently debuted its myQA Daily
, designed to combine workflow efficiency and high accuracy for measurements and analysis through multiple features, including 125 ionization chambers.
It is listed on the pan-European stock exchange NYSE EURONEXT.